Objective: To explore the clinical efficacy of different methods in the treatment of early neurological deterioration (END) of branch atherosclerotic disease (BAD). Methods: According to the different treatment methods, 95 consecutive patients with progressive stroke in BAD were classified into two groups: a dual antiplatelet therapy group (49 cases) and an antiplatelet combined anticoagulation group (46 cases). The dual antiplatelet therapy group was treated by aspirin and clopidogrel, the antiplatelet combined anticoagulation group was managed with aspirin plus enoxaparin sodium. Both groups accepted other clinical routines for the treatment of cerebral infarction such as statins, edaravone, dl-3-n-butylphthalide were same. The NIHSS score and Barthel index (BI) of the patients when progression and discharge were assessed respectively. The improvement of neurological function and activities of daily living (ADL) ability was compared in both groups. The plasma CRP concentration was measured at the time of progression and discharge, the effect of both treatments on CRP was compared. Results: NIHSS scores decreased significantly in both groups at discharge (P<0.05), and BI scores increased significantly (P<0.05). The degree of improvement of neurological function and the ability of ADL in antiplatelet combined anticoagulation group were significantly higher than those in the dual antiplatelet therapy group (P<0.05). Plasma CRP level in each group was significantly lower than that in BAD progression (P<0.05). Plasma CRP in antiplatelet combined anticoagulation group was significantly higher than that of the dual antiplatelet therapy group (P<0.05). Conclusion: Both dual antiplatelet therapy and aspirin combined with enoxaparin anticoagulation can improve END in patients with BAD progressive stroke. Furthermore, the clinical efficacy of aspirin combined with enoxaparin therapy is better than aspirin and clopidogrel antiplatelet therapy.